In The Claims:

Upon entry, this listing of claims will replace all prior versions or listings of claims in the present application:

Claim 1. (**currently amended**) A compound having the formula:

C'



wherein B is a ~~**heterocyclic ring derived from a**~~ purine ~~**or pyrimidine**~~ moiety, and pharmaceutically acceptable salts, and prodrugs, thereof.

Claims 2 – 28. (cancelled)

Claim 29. (**currently amended**) A compound having the formula:



wherein B is a ~~**heterocyclic ring derived from a**~~ purine ~~**or pyrimidine**~~ moiety, and pharmaceutically acceptable salts, and prodrugs, thereof.

Claim 30. (**currently amended**) The compound of Claims 1 or 29, wherein B is selected from the group consisting of 6-aminopurine, 2,6-diaminopurine, 2-amino-6-cyclopropylaminopurine, 6-hydroxypurine, 2-amino-6-halo substituted purine, 2-amino-6-alkoxy substituted purine, 2-amino-6-hydroxypurine, 3-deazapurine, 7-deazapurine, and 8-azapurine, ~~**cytosine, 5-halo substituted cytosine, 5-halo substituted cytosine, 5-alkyl substituted cytosine, thymine, uracil and 6-azapyrimidine**~~.

Claim 31. (**currently amended**) The compound of Claims 1 or 29, wherein B is selected from the group consisting of adenin-N^9-yl, guanin-N^9-yl, ~~**cytosin-N1-yl,**~~

~~2,6-diaminopurine~~ 2,6-diaminopurine-N^9-yl, 2-amino-6-cyclopropylaminopurin-N^9-yl and 2-amino-6-chloropurin-N^9-yl.

Claim 32. (**currently amended**) An antiviral compound selected from the group consisting of syn-N^9-2-hydroxymethylcyclopropylidenemethyl)adenine, syn-N^9-(2-hydroxymethylcyclopropylidenemethyl)guanine, ~~syn-N1-2-hydroxymethylcyclopropylidenemethyl)-cytosine,~~ syn-2,6-diamino-N^9-2-hydroxymethylcyclo-propylidenemethyl)purine, syn-2-amino-6-cyclopropylamino-N^9-2-hydroxymethylcyclopropylidenemethyl)purine and pharmaceutically acceptable salts, and prodrugs, thereof.

C1

Claim 33. (previously amended) An antiviral compound selected from the group consisting of methyl-phenyl-phosphoro-L-alaninate of syn-N^9-(2-hydroxymethylcyclo-propylidenemethyl)adenine, methyl phenyl-phosphoro-L-alaninate of anti-N^2-(2-hydroxymethylcyclo-propylidenemethyl)adenine and pharmaceutically acceptable salts, and prodrugs, thereof.

Claim 34. (**currently amended**) A composition comprising a compound of Claims 1 and **29** ~~29-33~~ and a pharmaceutically acceptable carrier.

Claim 35. (**currently amended**) A method of treating mammals infected with a virus **selected from the group consisting of HCMV, HSV-1, HSV-2, HHV-6, HIV, EBV, and HBV** comprising the step of administering to the mammal an antiviral compound selected from the group consisting of the compounds of Claims 1 and **29** ~~29-34~~.

Claim 36. (original) The method of Claim 35, wherein said mammal is a human.

Claim 37. (original) The method of Claim 35, wherein said virus is a human herpes virus.

Claim 38. (original) The method of Claim 35, wherein said virus is a human immunodeficiency virus.

Claim 39. (original) The method of Claim 35, wherein said virus is hepatitis B virus.

Claim 40. (original) The method of Claim 35, further comprising the step of administering an additional antiviral compound.

Claim 41. (original) The method of Claim 40, wherein the additional antiviral compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddI, ddC, d4T, and combinations thereof.

C1 **Claim 42.** (**new**) The compound having the formula:



wherein B is 2-amino-6-cyclopropylaminopurin-N^9-yl, and pharmaceutically acceptable salts, and prodrugs, thereof.

Claim 43. (**new**) The (S)-(+)-enantiomer of the compound of claim ~~42~~.

Claim 44. (**new**) The (R)-(–)-enantiomer of the compound of claim ~~42~~.

Claim 45. (**new**) A composition comprising a compound of Claims 42-44 and a pharmaceutically acceptable carrier.

Claim 46. (**new**) A method of treating mammals infected with a virus selected from the group consisting of HCMV, HSV-1, HSV-2, HHV-6, HIV, EBV, and HBV comprising the step of administering to the mammal an antiviral compound selected from the group consisting of the compounds of Claims 42-44.